Sonas Pharma

Sonas Pharma, based in the UK, specializes in pioneering early-stage cannabinoid therapies aimed at neurological management and metabolic health, targeting conditions like epilepsy and obesity through innovative pharmaceutical development. Sonas Pharma focuses on the clinical development of precision cannabinoid therapies. The company, headquartered in Belfast, UK, co-founded by Dr Chris Hayes (CEO) and Dr Emma Cheetha. The latest funding round took place in February 2026, as part of their fundraising efforts, involving a new investor, SFC Capital, and participation from Clarendon Fund Managers.

The company has completed a total of 1 deal to date. Sonas Pharma specializes in the clinical development of precision cannabinoid therapies, primarily targeting neurological management and metabolic health. The company is focusing on innovative solutions for epilepsy and obesity, utilizing advanced molecular engineering and formulation strategies to create high-precision pharmaceuticals. By refining targeted molecules, Sonas Pharma aims to improve therapeutic outcomes while minimizing off-target effects and drug-drug interactions, thus addressing significant gaps in existing cannabinoid treatments.

Their portfolio includes a new generation of cannabinoid medicines that extend beyond traditional CBD products, aiming to reduce dose burden and metabolic waste while enhancing clinical efficacy. These products are anticipated to cater to healthcare providers and patients across various geographical markets, including Europe and North America, where there is a rising demand for effective cannabinoid-based therapies for these conditions. Sonas Pharma has recently closed a pre-seed funding round, a critical step in supporting its revenue-generating activities through the development of innovative therapies. The company engages in strategic partnerships and collaborations with investors and pharmaceutical stakeholders to bring its cannabinoid-based products to market.

Revenue streams are likely to include licensing agreements, which facilitate the distribution of their patented medicines, and potential direct-to-consumer sales through healthcare providers. The transaction structure emphasizes establishing long-term relationships with clients, such as hospitals and clinics, that can utilize these therapies in treating patients. Specific pricing plans and costs associated with the flagship cannabinoid products have not been disclosed, but the company’s focus on comprehensive patent protection indicates a strategic intent to maintain a competitive advantage and ensure market exclusivity. In February 2026, Sonas Pharma raised an undisclosed amount of pre-seed funding led by SFC Capital, with participation from Clarendon Fund Managers.

The company will use the funding to support research on metabolic and neurological disorders, develop early-stage laboratory capabilities, and expand its team. Sonas Pharma aims to launch new cannabinoid products specifically targeting epilepsy and obesity, with plans to enter European and North American markets by 2027. This strategy aligns with their objective of addressing unmet needs in cannabinoid therapies and increasing their market presence.